Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovaries and uterus of tamoxifen-treated rats

Basit Öğe Kaydı
dc.contributor.authorCirpan, T.
dc.contributor.authorTerek, M. C.
dc.contributor.authorUlukus, M.
dc.contributor.authorUlukus, E. C.
dc.contributor.authorAkman, L.
dc.contributor.authorKanit, L.
dc.date.accessioned2019-10-27T19:57:03Z
dc.date.available2019-10-27T19:57:03Z
dc.date.issued2008
dc.departmentEge Üniversitesien_US
dc.description.abstractThe aim of the study was to evaluate the immunohistochemical expression of cell proliferation and apoptosis markers in the ovaries and uterus of tamoxifen-treated rats. Twelve rats (150-200 g) were divided into two equal groups. The study group received daily intraperitoneal injections of tamoxifen dissolved in 5% dimethyl sulfoxide (n = 6). The control group received only the vehicle (n = 6). The rats were sacrificed at the 20th day of injection and were perfused. The ovaries and uterus of the rats were extracted. The sections were immunohistochemically stained with cell proliferation marker Ki-67 and the apoptosis markers PTEN and CD95. The expressions of the markers were quantified by a semiquantitative H-score method in myometrium, endometrial glands, ovarian surface epithelium, ovarian follicles, corpus luteum, and ovarian stroma separately. The mean H-scores of CD95 and PTEN obtained from myometrium, glandular endometrium, ovarian surface epithelium, ovarian follicles, corpus luteum, and ovarian stroma did not show significant difference between the study and the control groups. Proliferative index (Ki-67) of endometrial glands was significantly higher in the study group than in the control group (P < 0.05). In addition, proliferative index (Ki-67) of corpus luteum was significantly higher in the study group than in the control group (P < 0.05). Tamoxifen treatment has a potential to stimulate the cell proliferation of endometrial glands and corpus luteum in tamoxifen-treated rats. Apoptosis markers of PTEN and CD95 did not demonstrate significant difference after the tamoxifen treatment.en_US
dc.identifier.doi10.1111/j.1525-1438.2007.00956.xen_US
dc.identifier.endpage145en_US
dc.identifier.issn1048-891X
dc.identifier.issue1en_US
dc.identifier.pmid17466037en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage141en_US
dc.identifier.urihttps://doi.org/10.1111/j.1525-1438.2007.00956.x
dc.identifier.urihttps://hdl.handle.net/11454/40898
dc.identifier.volume18en_US
dc.identifier.wosWOS:000252208100023en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBlackwell Publishingen_US
dc.relation.ispartofInternational Journal of Gynecological Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectapoptosisen_US
dc.subjectCD95en_US
dc.subjectKi-67en_US
dc.subjectovaryen_US
dc.subjectPTENen_US
dc.subjectraten_US
dc.subjecttamoxifenen_US
dc.subjectuterusen_US
dc.titleImmunohistochemical evaluation of cell proliferation and apoptosis markers in ovaries and uterus of tamoxifen-treated ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu